- Conditions
- Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
- Interventions
- CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 21,191
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Budesonide 360ug, Budesonide 720ug, Budesonide 1440ug, Budesonide720ug 4 times, Placebo
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cancer, Lymphoma
- Interventions
- XL228
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Interventions
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting
- Behavioral · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Asthma
- Interventions
- GW685698X, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 95
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
- Conditions
- Asthma, Bronchoconstriction
- Interventions
- Levalbuterol HFA MDI, Racemic Albuterol
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
- Conditions
- Asthma
- Interventions
- Vitamin D 3 cholecalciferol, Vitamin D3
- Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 876 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2023
- U.S. locations
- 3
- States / cities
- San Diego, California • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Zydelig
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet Transplantation and Bone Marrow
- Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hematologic Malignancies
- Interventions
- L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine, Cyclophosphamide, Tacrolimus, Mesna, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Hematopoietic stem cell transplantation (HSCT)
- Drug · Biological · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Thyroid Eye Disease, TED
- Interventions
- MHB018A injection, MHB018A injection Placebo
- Drug
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- HM12460A, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes
- Interventions
- Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
- Drug
- Lead sponsor
- Edwin Horwitz
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections, Protease Inhibitor
- Interventions
- Atazanavir Sulphate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
- Conditions
- Food Protein-Induced Enterocolitis Syndrome
- Interventions
- Supervised Low-Dose Oral Food Challenge (OFC), At-Home Low-Dose Oral Food Challenge (OFC), Supervised High-Dose Oral Food Challenge (OFC)
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 1 Year to 60 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- filgrastim, clofarabine, melphalan, mycophenolate mofetil, tacrolimus, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 0 Years to 54 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pemphigus
- Interventions
- Sirolimus (formerly known as Rapamycin)
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- B-cell Lymphoma
- Interventions
- Bevacizumab, Rituximab, CHOP, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 17
- States / cities
- La Jolla, California • Whittier, California • Aurora, Colorado + 14 more
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more
- Conditions
- Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
- Interventions
- No intervention
- Other
- Lead sponsor
- T1D Exchange, United States
- Other
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
- Interventions
- Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Bridging Radiation Therapy
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more